Vivos Therapeutics Ownership | Who Owns Vivos Therapeutics?

Overview RevenueFinancials Chart Transcripts

Vivos Therapeutics Ownership Summary

Vivos Therapeutics is owned by 0.33% institutional investors, and 99.67% retail investors. Fidelity Extended Market Index is the top mutual fund, with 0.39% of its assets in Vivos Therapeutics shares.

VVOS Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Vivos Therapeutics	0.33%	-	99.67%
Sector	Healthcare Stocks	49.73%	8.84%	41.43%
Industry	Medical Device Stocks	53.39%	8.20%	38.41%

Institutional Shareholders

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2023	1	-96.15%	4,000	-99.91%	-	0.15%	-	-100.00%	-	-100.00%
Sep 30, 2023	26	-13.33%	4,475,024	-4.63%	14	4.16%	6	-45.45%	4	-42.86%
Jun 30, 2023	30	-3.23%	4,692,243	-6.39%	18	4.62%	11	-15.38%	7	40.00%
Mar 31, 2023	31	14.81%	5,012,314	220.31%	20	43.77%	13	8.33%	5	-16.67%
Dec 31, 2022	27	-	1,564,827	-26.28%	6	6.80%	12	50.00%	6	-25.00%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Fidelity Extended Market Index	18.66K	0.39%	2.78K
Vanguard Institutional Extnd Mkt Idx Tr	10.58K	0.22%	-
Dimensional US Core Equity 2 ETF	4.87K	0.10%	-
Fidelity Series Total Market Index	4.31K	0.09%	3.15K
Spartan Extended Market Index Pool E	2.48K	0.05%	2.48K
Fidelity Nasdaq Composite Index	1.46K	0.03%	-
Dimensional US Sustainability Core 1 ETF	1.23K	0.03%	-
Spartan Total Market Index Pool E	993.00	0.02%	-
Fidelity Total Market Index	900.00	0.02%	-
NT Ext Equity Mkt Idx Fd - L	569.00	0.01%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Jun 20, 2023	Huntsman Ronald Kirk	Chief Executive Officer	Buy	$7.42K
Jun 16, 2023	Huntsman Ronald Kirk	Chief Executive Officer	Buy	$5.40K
Jun 16, 2023	Huntsman Ronald Kirk	Chief Executive Officer	Buy	$2.65K
Jun 15, 2023	Huntsman Ronald Kirk	Chief Executive Officer	Buy	$10.50
Jun 14, 2023	Huntsman Ronald Kirk	Chief Executive Officer	Buy	$4.90K

Insider Transactions Trends

Date	Buy	Sell
2024 Q4	-	-
2024 Q2	-	-
2023 Q2	5	-
2022 Q4	1	-
2022 Q2	1	-

VVOS Ownership FAQ

Who Owns Vivos Therapeutics?

Vivos Therapeutics shareholders are primarily institutional investors at 0.33%, followed by 0% insiders and 0% retail investors. The average institutional ownership in Vivos Therapeutics's industry, Medical Device Stocks, is 53.39%, which Vivos Therapeutics falls below.

Does Blackrock own Vivos Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Vivos Therapeutics.

Who is the top mutual fund holder of Vivos Therapeutics shares?

Fidelity Extended Market Index is the top mutual fund holder of Vivos Therapeutics shares, with 0.39% of its total shares outstanding invested in 18.66K Vivos Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools